Prevalence of Self-reported Neurologic and Ocular Symptoms in Early Syphilis Cases.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
15 03 2021
Historique:
received: 13 11 2019
accepted: 25 02 2020
pubmed: 28 2 2020
medline: 29 4 2021
entrez: 28 2 2020
Statut: ppublish

Résumé

Neurosyphilis, a complication of syphilis, can occur at any stage of infection. Measuring the prevalence of neurosyphilis is challenging, and there are limited data on the prevalence of neurologic or ocular symptoms among patients with syphilis. We sought to describe the prevalence of neurologic and/or ocular symptoms among early syphilis (ES) cases and the clinical management of symptomatic cases enrolled in the STD Surveillance Network (SSuN) Neuro/Ocular Syphilis Surveillance project. Persons diagnosed with ES were selected for interviews based on current health department protocols in 5 participating SSuN jurisdictions from November 2016 through October 2017. All interviewed ES cases were screened for self-reported neurologic and/or ocular symptoms. Additional clinical information on diagnostic testing and treatment for cases concerning for neurosyphilis/ocular syphilis was obtained from providers. Among 9123 patients with ES who were interviewed, 151 (1.7%; 95% confidence interval [CI], 1.4%-1.9%) reported ≥ 1 neurologic or ocular symptom. Of the 53 (35%) who underwent lumbar puncture, 22 (42%) had documented abnormal cerebrospinal fluid, of which 21 (95%) were treated for neurosyphilis/ocular syphilis. Among the remaining 98 symptomatic patients with no documented lumbar puncture (65%), 12 (12%) were treated for and/or clinically diagnosed with neurosyphilis/ocular syphilis. We observed a low prevalence of self-reported neurologic and/or ocular symptoms in interviewed ES cases. Approximately one-third of ES cases who self-reported symptoms underwent further recommended diagnostic evaluation. Understanding barriers to appropriate clinical evaluation is important to ensuring appropriate management of patients with possible neurologic and/or ocular manifestations of syphilis.

Sections du résumé

BACKGROUND
Neurosyphilis, a complication of syphilis, can occur at any stage of infection. Measuring the prevalence of neurosyphilis is challenging, and there are limited data on the prevalence of neurologic or ocular symptoms among patients with syphilis. We sought to describe the prevalence of neurologic and/or ocular symptoms among early syphilis (ES) cases and the clinical management of symptomatic cases enrolled in the STD Surveillance Network (SSuN) Neuro/Ocular Syphilis Surveillance project.
METHODS
Persons diagnosed with ES were selected for interviews based on current health department protocols in 5 participating SSuN jurisdictions from November 2016 through October 2017. All interviewed ES cases were screened for self-reported neurologic and/or ocular symptoms. Additional clinical information on diagnostic testing and treatment for cases concerning for neurosyphilis/ocular syphilis was obtained from providers.
RESULTS
Among 9123 patients with ES who were interviewed, 151 (1.7%; 95% confidence interval [CI], 1.4%-1.9%) reported ≥ 1 neurologic or ocular symptom. Of the 53 (35%) who underwent lumbar puncture, 22 (42%) had documented abnormal cerebrospinal fluid, of which 21 (95%) were treated for neurosyphilis/ocular syphilis. Among the remaining 98 symptomatic patients with no documented lumbar puncture (65%), 12 (12%) were treated for and/or clinically diagnosed with neurosyphilis/ocular syphilis.
CONCLUSIONS
We observed a low prevalence of self-reported neurologic and/or ocular symptoms in interviewed ES cases. Approximately one-third of ES cases who self-reported symptoms underwent further recommended diagnostic evaluation. Understanding barriers to appropriate clinical evaluation is important to ensuring appropriate management of patients with possible neurologic and/or ocular manifestations of syphilis.

Identifiants

pubmed: 32103243
pii: 5758075
doi: 10.1093/cid/ciaa180
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

961-967

Informations de copyright

Published by Oxford University Press for the Infectious Diseases Society of America 2020.

Auteurs

Laura A S Quilter (LAS)

Epidemic Intelligence Service, Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Alex de Voux (A)

Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Rachel M Amiya (RM)

Washington State Department of Health, Shoreline, Washington, USA.

Erin Davies (E)

Washington State Department of Health, Shoreline, Washington, USA.

Robin R Hennessy (RR)

Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
New York City Department of Health and Mental Hygiene, New York, New York, USA.

Roxanne P Kerani (RP)

Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.

Robbie Madera (R)

Philadelphia Department of Public Health, Philadelphia, Pennsylvania, USA.

James Matthias (J)

Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Florida Department of Health, Tallahassee, Florida, USA.

Victoria M Pearson (VM)

Florida Department of Health, Tallahassee, Florida, USA.

Jaime K Walters (JK)

Multnomah County Health Department, Portland, Oregon, USA.

Craig Wilson (C)

Florida Department of Health, Tallahassee, Florida, USA.

Sarah Kidd (S)

Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Elizabeth Torrone (E)

Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH